Cargando…
Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension
We aim to determine whether nebivolol has a better effect on endothelial dysfunction compared with other β-blockers or other classes of antihypertensive drugs. Searches of the PubMed, Embase etc. were performed to analyze all the randomized controlled trials using nebivolol to treat essential hypert...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201558/ https://www.ncbi.nlm.nih.gov/pubmed/32342981 http://dx.doi.org/10.1042/BSR20200436 |
_version_ | 1783529558967844864 |
---|---|
author | Li, Bingwei Zhang, Qiuju Zhang, Honggang Wang, Chunxiao Xiu, Ruijuan |
author_facet | Li, Bingwei Zhang, Qiuju Zhang, Honggang Wang, Chunxiao Xiu, Ruijuan |
author_sort | Li, Bingwei |
collection | PubMed |
description | We aim to determine whether nebivolol has a better effect on endothelial dysfunction compared with other β-blockers or other classes of antihypertensive drugs. Searches of the PubMed, Embase etc. were performed to analyze all the randomized controlled trials using nebivolol to treat essential hypertension. The primary end points included a measurement of peripheral endothelial function by brachial flow mediated vasodilatation (FMD) or forearm blood flow (FBF). A random-effect model was used to perform the meta-analysis when the studies showed significant heterogeneity, otherwise a descriptive analysis was conducted. Ten studies (689 patients) were included in qualitative analysis, four of which were included in quantitative synthesis. Meta-analysis showed that the changed FMD value before and after treatment with nebivolol was not statistically different from those treated with other β-blockers [mean difference = 1.12, 95% confidence interval (CI): −0.56, 2.81, P=0.19]. Descriptive analysis indicated that nebivolol did not have a better endothelium-protective effect than other classes of antihypertensive drugs including olmesartan and perindopril. Nebivolol is not a unique endothelial function-protective agent distinguished from other β-blockers or other classes of antihypertensive drugs. Reversal of endothelial dysfunction is a key point in the prevention and therapy of essential hypertension. |
format | Online Article Text |
id | pubmed-7201558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72015582020-06-10 Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension Li, Bingwei Zhang, Qiuju Zhang, Honggang Wang, Chunxiao Xiu, Ruijuan Biosci Rep Cardiovascular System & Vascular Biology We aim to determine whether nebivolol has a better effect on endothelial dysfunction compared with other β-blockers or other classes of antihypertensive drugs. Searches of the PubMed, Embase etc. were performed to analyze all the randomized controlled trials using nebivolol to treat essential hypertension. The primary end points included a measurement of peripheral endothelial function by brachial flow mediated vasodilatation (FMD) or forearm blood flow (FBF). A random-effect model was used to perform the meta-analysis when the studies showed significant heterogeneity, otherwise a descriptive analysis was conducted. Ten studies (689 patients) were included in qualitative analysis, four of which were included in quantitative synthesis. Meta-analysis showed that the changed FMD value before and after treatment with nebivolol was not statistically different from those treated with other β-blockers [mean difference = 1.12, 95% confidence interval (CI): −0.56, 2.81, P=0.19]. Descriptive analysis indicated that nebivolol did not have a better endothelium-protective effect than other classes of antihypertensive drugs including olmesartan and perindopril. Nebivolol is not a unique endothelial function-protective agent distinguished from other β-blockers or other classes of antihypertensive drugs. Reversal of endothelial dysfunction is a key point in the prevention and therapy of essential hypertension. Portland Press Ltd. 2020-05-05 /pmc/articles/PMC7201558/ /pubmed/32342981 http://dx.doi.org/10.1042/BSR20200436 Text en © 2020 The Author(s). https://creativecommons.org/licenses/by/4.0/ This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). |
spellingShingle | Cardiovascular System & Vascular Biology Li, Bingwei Zhang, Qiuju Zhang, Honggang Wang, Chunxiao Xiu, Ruijuan Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension |
title | Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension |
title_full | Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension |
title_fullStr | Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension |
title_full_unstemmed | Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension |
title_short | Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension |
title_sort | effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension |
topic | Cardiovascular System & Vascular Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201558/ https://www.ncbi.nlm.nih.gov/pubmed/32342981 http://dx.doi.org/10.1042/BSR20200436 |
work_keys_str_mv | AT libingwei effectsofnebivololversusotherantihypertensivedrugsontheendothelialdysfunctioninpatientswithessentialhypertension AT zhangqiuju effectsofnebivololversusotherantihypertensivedrugsontheendothelialdysfunctioninpatientswithessentialhypertension AT zhanghonggang effectsofnebivololversusotherantihypertensivedrugsontheendothelialdysfunctioninpatientswithessentialhypertension AT wangchunxiao effectsofnebivololversusotherantihypertensivedrugsontheendothelialdysfunctioninpatientswithessentialhypertension AT xiuruijuan effectsofnebivololversusotherantihypertensivedrugsontheendothelialdysfunctioninpatientswithessentialhypertension |